Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Equity Average (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Equity Average for 6 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 51.17% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 51.17% decrease, with the full-year FY2024 number at $1.5 million, up 165.31% from a year prior.
  • Equity Average was $2.0 million for Q3 2025 at Ensysce Biosciences, down from $2.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $5.1 million in Q4 2024 to a low of -$7.0 million in Q1 2021.
  • A 5-year average of $74034.1 and a median of $1.4 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 250.97% in 2022, then skyrocketed 1931.59% in 2024.
  • Ensysce Biosciences' Equity Average stood at -$4.3 million in 2021, then dropped by 22.34% to -$5.2 million in 2022, then surged by 104.85% to $253204.0 in 2023, then surged by 1931.59% to $5.1 million in 2024, then tumbled by 61.75% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Equity Average are $2.0 million (Q3 2025), $2.9 million (Q2 2025), and $3.2 million (Q1 2025).